In this study, we observed heterogeneous FGFR protein expression across cell lines, with FGFR2 absent in all tested GSC, consistent with Ohashi et al. findings, who reported reduced FGFR2 expression in high-grade gliomas [41]. The gene discussed is FGFR2; the disease is central nervous system cancer.